[{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kynexis Therapeutics \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"AMZ002","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amzell B.V \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amzell B.V \/ Inapplicable"},{"orgOrder":0,"company":"PureIMS","sponsor":"Cooperative Clinical Drug Research and Development AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureIMS \/ Cooperative Clinical Drug Research and Development AG","highestDevelopmentStatusID":"6","companyTruncated":"PureIMS \/ Cooperative Clinical Drug Research and Development AG"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
KYN-5356 is a small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II. It is being evaluated for the treatment of cognitive impairment associated with schizophrenia.
Details :
KYN-5356 is a clinical-stage small molecule targeting KAT-II in the kynurenine pathway. It is being evaluated in Phase 1 for cognitive impairment associated with schizophrenia.
Details :
The phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population.
Reset All
